Pharmacokinetics

Pharmacokinetics (from the Ancient Greek pharmakon, "drug," and kinetikos, "putting in motion") is the quantitative branch of pharmacology that characterizes the time course of xenobiotic concentrations across biological fluids, tissues, and excreta. By applying differential equations and mass-balance principles to the four physiological processes of ADMET—Absorption, Distribution, Metabolism, and Excretion—pharmacokinetics establishes the mathematical relationship between an administered dosing regimen and the resulting unbound concentration–time profile C(t) at the pharmacological site of action.

Whereas pharmacodynamics describes how a given concentration of drug interacts with receptors or enzymes to produce a biological effect, pharmacokinetics governs the delivery and persistence of the molecule in the organism. First formalized into compartmental rate equations by Torsten Teorell in 1937 and named by Friedrich Hartmut Dost in 1953, pharmacokinetic analysis underpins clinical dose selection, dosing interval optimization, therapeutic index maintenance, and regulatory bioequivalence evaluation.

Bioavailability and Apparent Volume of Distribution

When a drug is administered extravascularly (such as orally, subcutaneously, or intramuscularly), only a fraction of the administered dose reaches the systemic arterial circulation intact. Absolute bioavailability (F) is defined experimentally by comparing the dose-normalized Area Under the Concentration–Time Curve (AUC_0→∞) after oral administration to that after an intravenous (IV) bolus reference dose (F_IV = 1.0):

F = (AUC_oral / Dose_oral) / (AUC_IV / Dose_IV) = f_a · f_g · f_h

Here, f_a is the fraction of dose absorbed across the apical enterocyte membrane, f_g is the fraction escaping gut-wall biotransformation (principally via intestinal CYP3A4 and efflux by membrane drug transporters like P-glycoprotein), and f_h = 1 − E_H is the fraction escaping first-pass hepatic extraction before reaching the vena cava.

Once in systemic circulation, a drug distributes reversibly between intravascular plasma and extravascular peripheral tissues. The apparent volume of distribution (V_d) is a proportionality constant relating the total amount of drug in the body (A_body) to its measured plasma concentration (C_p):

V_d = A_body / C_p

Under physiological steady-state equilibrium, the steady-state volume of distribution (V_d,ss) is governed by the Oie–Tozer / Gillette relationship:

V_d,ss = V_p + V_t · (f_u / f_u,t)

where V_p (~3 L or 0.04 L/kg in a 70 kg adult) is physiological plasma volume, V_t (~39 L) is extravascular tissue water volume, f_u is the unbound fraction in plasma, and f_u,t is the unbound fraction in tissue. Macromolecules such as monoclonal antibody therapy agents or highly albumin-bound acidic drugs (such as warfarin, f_u ≈ 0.01) exhibit small volumes of distribution (V_d ≈ 3–8 L) restricted to plasma and extracellular fluid. Conversely, lipophilic weak bases (such as chloroquine, amiodarone, or tricyclic antidepressants) undergo extensive intracellular ion trapping in acidic lysosomes (f_u,t ≪ f_u), yielding apparent volumes of distribution of 500 to >10,000 L that far exceed total anatomical body volume (~42 L).

Organ Clearance and the Well-Stirred Hepatic Model

Clearance (CL) is the fundamental volume-per-time parameter (mL/min or L/h) measuring the efficiency of irreversible drug elimination from systemic blood or plasma. Total systemic clearance is the additive sum of individual clearing organs:

CL_tot = CL_hepatic + CL_renal + CL_other

For any eliminating organ perfused at blood flow rate Q with arterial inflow concentration C_in and venous outflow concentration C_out, the steady-state extraction ratio (E) and organ clearance are:

E = (C_in − C_out) / C_in , CL_organ = Q · E

In 1973, Malcolm Rowland, Leslie Benet, and Graham Graham formulated the well-stirred (venous equilibration) hepatic clearance model, which relates hepatic blood clearance (CL_H) to hepatic blood flow (Q_H ≈ 1.5 L/min in humans), the unbound fraction in blood (f_u,b), and the hepatocellular enzymatic intrinsic clearance (CL_int = V_max / K_m) of Phase I and Phase II drug metabolism:

CL_H = (Q_H · f_u,b · CL_int) / (Q_H + f_u,b · CL_int)

This equation partitions drugs into two limiting physiological regimes:

• High-Extraction Drugs (E_H > 0.7, where f_u,b · CL_int ≫ Q_H): Simplifies to CL_H ≈ Q_H (perfusion- or flow-limited clearance). Clearance is insensitive to changes in enzyme activity or protein binding but declines directly with reduced hepatic blood flow (e.g., congestive heart failure or cirrhosis). Examples include lidocaine, propranolol, verapamil, and morphine, all of which suffer extensive first-pass oral extraction (F = 1 − E_H < 0.30).
• Low-Extraction Drugs (E_H < 0.3, where f_u,b · CL_int ≪ Q_H): Simplifies to CL_H ≈ f_u,b · CL_int (capacity-limited clearance). Clearance is independent of hepatic blood flow but directly sensitive to enzyme induction or inhibition (drug–drug interactions) and variations in unbound fraction f_u,b. Examples include warfarin, phenytoin, diazepam, and theophylline.

One- and Two-Compartment Differential Equations and Half-Life

In a one-compartment open model with first-order elimination after an IV bolus dose, the rate of change of plasma concentration is proportional to the instantaneous concentration:

d*C* / d*t* = −*k*_e · C ⇒ C(t) = C₀ · e^−*k*_et

where C₀ = Dose / V_d is the initial concentration and k_e = CL / V_d is the first-order elimination rate constant (units of h⁻¹). Integrating C(t) from t = 0 to ∞ yields the fundamental mass-balance equation AUC_0→∞ = Dose / CL (or F · Dose / CL for oral dosing). The elimination half-life (t_1/2)—the time required for plasma concentration to decline by 50%—is a hybrid secondary parameter dependent on both V_d and CL:

t_1/2 = ln(2) / k_e = (ln(2) · V_d) / CL ≈ (0.693 · V_d) / CL

In a two-compartment model, the drug distributes rapidly into a central compartment (V₁, blood and richly perfused organs) and more slowly into a peripheral tissue compartment (V₂) with inter-compartmental rate constants k₁₂ and k₂₁. The plasma profile follows a bi-exponential decay, C(t) = A · e^−α*t* + B · e^−β*t*, exhibiting a steep initial distribution phase (α) followed by a shallower terminal elimination phase (β) with terminal half-life t_1/2,β = 0.693 / β.

First-Order Linear vs. Zero-Order Michaelis–Menten Kinetics

Most clinical drugs operate in the linear pharmacokinetic regime where therapeutic unbound concentrations are well below the Michaelis constant of metabolizing enzymes (C ≪ K_m). However, when plasma concentrations approach or exceed K_m, hepatic enzymes become saturated and elimination follows Michaelis–Menten kinetics:

−d*C* / d*t* = (V_max · C) / (K_m + C)

When C ≫ K_m, the rate reduces to a constant zero-order elimination rate (−d*C*/d*t* ≈ V_max), meaning a fixed mass (mg/h) rather than a fixed fraction (%/h) is eliminated per unit time. Classic clinical examples of zero-order saturation kinetics include ethanol (oxidized by alcohol dehydrogenase with K_m ≈ 10 mg/dL, clearing at a fixed ~7–10 g/h), phenytoin (hydroxylated by CYP2C9/2C19 with K_m ≈ 4–12 μg/mL right inside the therapeutic range of 10–20 μg/mL), and high-dose salicylates (aspirin). Under saturation kinetics, clearance decreases with rising concentration, half-life lengthens with dose, and small dose increments provoke disproportionate, supra-proportional surges in steady-state plasma concentrations.

Accumulation to Steady State and Loading vs. Maintenance Doses

When a drug is administered repeatedly at a fixed dosing interval τ, drug from subsequent doses accumulates until the mass eliminated during one interval equals the bioavailable mass absorbed (F · Dose). At this steady state, the average plasma concentration (C_ss,avg) depends solely on bioavailable dose rate and clearance:

C_ss,avg = (AUC_0→τ,ss) / τ = (F · Dose) / (CL · τ)

The degree of drug buildup relative to the first dose is quantified by the accumulation factor, R_acc = 1 / (1 − e^−*k*_eτ); when a drug is dosed once every half-life (τ = t_1/2), R_acc = 1 / (1 − 0.5) = 2.0. Crucially, the time required to reach steady state depends only on the elimination half-life t_1/2—reaching 50% in 1 t_1/2, 75% in 2 t_1/2, 87.5% in 3 t_1/2, 93.75% in 4 t_1/2, and 96.88% in 5 t_1/2—regardless of dose size. For drugs with long half-lives (such as digoxin with t_1/2 ≈ 36–48 h or amiodarone with t_1/2 ≈ 40–55 days) where immediate clinical efficacy is required, clinicians administer an initial loading dose (DL = [V_d · C_target] / F) to fill the volume of distribution, followed by a clearance-matched maintenance dose (MD = [CL · C_target · τ] / F).

Non-Compartmental Analysis (NCA) and Physiologically Based PK (PBPK)

In clinical trials, Non-Compartmental Analysis (NCA) estimates AUC_0→∞ directly from observed plasma concentrations via the linear-up/log-down trapezoidal rule and derives mean residence time (MRT = AUMC / AUC) without assuming a specific number of compartments. Complementing empirical models, Physiologically Based Pharmacokinetic (PBPK) modeling represents the human body as a network of anatomical organ compartments (liver, kidney, gut, brain, adipose, muscle) linked by physiological arterial and venous blood flows (Q_i) and tissue-to-plasma partition coefficients (K_p,i), enabling bottom-up in vitro–to–in vivo extrapolation (IVIVE) of pediatric scaling, organ impairment, and complex drug–drug interactions.

Why does doubling the maintenance dose of a linear drug double its steady-state concentration without changing the time required to reach steady state?

Under first-order linear pharmacokinetics, the fractional approach to steady state is governed by the exponential decay term (1 − exp(−*k*_et)), where k_e = 0.693 / t_1/2. Because t_1/2 = (0.693 · V_d) / CL is constant for a first-order drug, it always takes 4 to 5 half-lives to reach 93.75%–96.88% of the new steady state regardless of the dose administered. Doubling the maintenance dose rate (F · Dose / τ) doubles the asymptotic ceiling (C_ss,avg = [F · Dose] / [CL · τ]), so the drug reaches the old therapeutic threshold faster, but reaching the new doubled steady-state plateau still requires 4 to 5 half-lives.

How can an apparent volume of distribution (V_d) exceed the total physical volume of the human body?

The apparent volume of distribution (V_d = A_body / C_p) is not an anatomical volume; it is a theoretical volume of plasma that would be required to contain the total body burden of drug at the same concentration measured in venous plasma (C_p). When a lipophilic basic drug (such as chloroquine or amiodarone) partitions avidly into peripheral adipose tissue, cell membranes, or acidic lysosomes (f_u,t ≪ f_u), the remaining plasma concentration C_p becomes very small (<10 ng/mL), causing the ratio A_body / C_p to calculate to hundreds or thousands of liters.

Why is phenytoin dosing hazardous compared to drugs that follow first-order kinetics?

Phenytoin undergoes saturable hepatic hydroxylation via CYP2C9 and CYP2C19 with a Michaelis constant (K_m ≈ 4–12 μg/mL) that lies directly below and within its narrow therapeutic plasma range (10–20 μg/mL). Because the metabolizing enzymes operate near V_max saturation at therapeutic doses, steady-state concentration is governed by the non-linear relation C_ss = (K_m · R₀) / (V_max − R₀), where R₀ is the daily dose rate. As R₀ approaches V_max, a modest 20% increase in daily dose (e.g., from 300 mg/day to 360 mg/day) can cause plasma concentrations to surge two- to three-fold into neurotoxic ranges (>25–30 μg/mL), inducing nystagmus and ataxia.

1. Rowland, M., Benet, L. Z., & Graham, G. G. (1973). "Clearance Concepts in Pharmacokinetics." Journal of Pharmacokinetics and Biopharmaceutics, 1(2), 123–136. https://doi.org/10.1007/BF01059626
2. Benet, L. Z., & Zia-Amirhosseini, P. (1995). "Basic Principles of Pharmacokinetics." Toxicologic Pathology, 23(2), 115–123. https://doi.org/10.1177/019262339502300203
3. Toutain, P. L., & Bousquet-Mélou, A. (2004). "Plasma Terminal Half-Life." Journal of Veterinary Pharmacology and Therapeutics, 27(6), 427–439. https://doi.org/10.1111/j.1365-2885.2004.00600.x
4. Jones, H., & Rowland-Yeo, K. (2013). "Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development." CPT: Pharmacometrics & Systems Pharmacology, 2(8), e63. https://doi.org/10.1038/psp.2013.41